No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Thermo Fischer Scientific Reports the Launch of the First-Ever GMP- and Cleanroom-Compatible CO2 Incubator

Editor: What To Know

  • “To effectively meet this need, we have complemented the demonstrated recovery and uniformity capabilities of the Thermo Scientific Heracell VIOS CO2 Incubator and Thermo Scientific Forma Steri-Cycle CO2 incubators with exceptional cleanability and GMP-enabling features to deliver the first CO2 incubator that is specifically built for cleanroom use.
  • Featuring a robust stainless-steel exterior and IP54-compliant design, the Vios CR CO2 incubator can withstand the rigorous and repeated cleaning procedures that are integral to effective cleanroom management, enabling long-term use and maximum return on investment.
  • Thermo Fischer Scientific has launched a first-in-market CO2 incubator that combines optimal cell growth capabilities with certified cleanroom compatibility, effectively addressing the growing need among biotechnology, biopharmaceutical, and clinical laboratories for high-performance incubation systems that meet stringent cleanroom and cGMP standards.

Thermo Fischer Scientific has launched a first-in-market CO2 incubator that combines optimal cell growth capabilities with certified cleanroom compatibility, effectively addressing the growing need among biotechnology, biopharmaceutical, and clinical laboratories for high-performance incubation systems that meet stringent cleanroom and cGMP standards.

Thermo Fischer Scientific Heracell Vios CR CO2 Incubator expands the Thermo Scientific Cell Therapy Systems (CTS) Series laboratory equipment portfolio with a solution specifically designed for use in GMP environments. Consistent with Thermo Fisher’s history of proven incubator technology, the new system provides optimal cell growth for even the most sensitive high-value cell cultures.

This new Vios CR CO2 incubator boasts fully enclosed casing and electronics, minimizing particle emissions in sync with critical particulate control in a Grade A/B cleanroom. Operating on the patented Thermo Scientific THRIVE active airflow technology, which delivers homogenous cell growth conditions and rapid parameter recovery in less than 10 minutes, the system prioritizes cell culture protection. Dependable contamination control is enabled through in-chamber HEPA filtration, on-demand 180°C sterilization, and an optional 100% pure copper interior chamber.

Featuring a robust stainless-steel exterior and IP54-compliant design, the Vios CR CO2 incubator can withstand the rigorous and repeated cleaning procedures that are integral to effective cleanroom management, enabling long-term use and maximum return on investment. The system is compatible with the STERIS Vaporized Hydrogen Peroxide (VHP) decontamination method, facilitating easy integration into existing sterilization workflows. Furthermore, the new incubator features independent TÜV SÜD certification for compatibility with ISO Class 5 cleanrooms, allowing scientists to confidently and effectively plan their cleanrooms to meet strict air quality requirements.

“As innovative research is being rapidly translated into promising therapies, we have seen dramatic growth in demand for premium incubators that are suitably equipped for use in controlled environments,” said Douglas Wernerspach, senior business director, Laboratory Products Division at Thermo Fisher Scientific. “To effectively meet this need, we have complemented the demonstrated recovery and uniformity capabilities of the Thermo Scientific Heracell VIOS CO2 Incubator and Thermo Scientific Forma Steri-Cycle CO2 incubators with exceptional cleanability and GMP-enabling features to deliver the first CO2 incubator that is specifically built for cleanroom use. This marks the latest step in our journey to better support cell therapy developers as they seek to bring innovative new therapeutics to patients.”

The new incubator comes with a range of cleanroom-compatible accessory options, including stacking adapters and roller bases to facilitate easy insertion into established laboratory processes. In addition, a comprehensive cGMP documentation package with recommended cleaning procedures and preventative maintenance protocols supports user-friendly, time-efficient implementation and validation.

Other Biotechnology News

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Preci and Biopredic International Partner for Higher Performance of Suspended Pooled Hepatocytes with Extended Longevity and Large-scale Availability

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.

The Future of Biotechnology: Insights Into Cutting-Edge Developments

The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.

Advancing Patient Care: LyGenesis Doses First Patient in Phase 2a Trial

"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy